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ABSTRACT
Stem cell function declines with age largely due to the biochemical imbalances 
in their tissue niches, and this work demonstrates that aging imposes an elevation 
in transforming growth factor β (TGF-β) signaling in the neurogenic niche of the 
hippocampus, analogous to the previously demonstrated changes in the myogenic 
niche of skeletal muscle with age. Exploring the hypothesis that youthful calibration 
of key signaling pathways may enhance regeneration of multiple old tissues, we 
found that systemically attenuating TGF-β signaling with a single drug simultaneously 
enhanced neurogenesis and muscle regeneration in the same old mice, findings 
further substantiated via genetic perturbations. At the levels of cellular mechanism, 
our results establish that the age-specific increase in TGF-β1 in the stem cell niches of 
aged hippocampus involves microglia and that such an increase is pro-inflammatory 
both in brain and muscle, as assayed by the elevated expression of β2 microglobulin 
(B2M), a component of MHC class I molecules. These findings suggest that at high 
levels typical of aged tissues, TGF-β1 promotes inflammation instead of its canonical 
role in attenuating immune responses. In agreement with this conclusion, inhibition 
of TGF-β1 signaling normalized B2M to young levels in both studied tissues.
INTRODUCTION
Adult stem cells persist in the body as we age, but 
their regenerative capacity declines over time, leading to 
an inability of tissues and organs to maintain homeostasis 
and repair damage with advancing age. Evidence suggests 
that the intrinsic capacity of some tissue stem cells, such 
as in muscle, for tissue maintenance and repair does not 
drastically decline with age. Rather, molecular changes in 
the stem cell microenvironments or niches contribute to 
or account for diminished stem cell regenerative potential 
in several tissue types, ultimately leading to tissue 
aging. Such changes in stem cell microenvironments 
that negatively regulate stem cell function have been 
observed in aged skeletal muscle, brain, skin, blood, 
and bone [1]. Considering that the same morphogenic 
signal transduction pathways – including Notch, Wnt, 
transforming growth factor β (TGF-β), fibroblast growth 
factor (FGF), Sonic hedgehog (Shh), and others – 
regulate adult stem cell behavior in different tissues [2], 
it is possible that age-related changes in these pathways 
that lead to diminished stem cell regeneration are also 
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conserved among multiple organ systems, such as brain 
and muscle. Furthermore, complex interplays between 
systemic and local changes in specific signaling factors 
with age have been shown to inhibit stem cell mediated 
tissue regeneration [3–9], and these interactions may also 
be conserved across tissues.
Neurogenesis occurs throughout life in the 
subgranular zone (SGZ) of the dentate gyrus (DG) of 
the hippocampus and the subventricular zone (SVZ) of the 
lateral ventricles in mammals, via differentiation of adult 
neural stem cells (NSCs) into excitatory granule neurons 
and inhibitory olfactory bulb interneurons, respectively 
(Ming & Song, 2005). Hippocampal neurogenesis is 
believed to modulate new memory formation, while SVZ 
neurogenesis plays a role in sensory functions [10–12]. 
Hippocampal neurogenesis, however, severely declines 
with age in rodents and primates [13–15]. In addition, 
SGZ neurogenesis is very active in humans and exhibits 
a steady decline in both NSC number and function with 
age [15–17], though the significance of the SVZ to human 
biology and health is unclear as this region does not 
exhibit active neurogenesis leading to maintenance of 
olfactory functions in adult humans [18]. Skeletal muscle 
regeneration also occurs throughout life, though muscle 
loses its regenerative capacity with age due to the failure 
of satellite cells (muscle stem cells) to divide and generate 
fusion competent myoblasts and terminally differentiated 
myofibers in response to muscle injury or attrition [1]. 
Consequentially, the replacement of the damaged tissue 
with new muscle fibers becomes inefficient with age, 
and instead scarring and inflammation persist [19, 20]. 
Considering that TGF-β regulates adult stem cell behavior 
in various tissues [1, 21–24], including in brain and 
muscle, we hypothesized that age-related elevation in the 
intensity of this pathway may contribute to diminished 
stem cell regeneration in the hippocampal niche, which 
combined with our prior results with the skeletal muscle 
stem cell niche would demonstrate conservation of signal 
transduction changes with age.
TGF-β1 is a multi-functional cytokine that becomes 
elevated with age both in circulation and locally in several 
tissues, including the muscle and brain [6, 25]. Such 
changes in the intensity of TGF- β/pSmad2,3 signaling – 
with aging, pathology, or experimental induction – have 
been shown to perturb homeostasis of such diverse tissues 
as muscle, bone and cartilage, the subventricular zone 
of the brain, vasculature, the hematopoietic/immune 
system, heart and skin [21–24, 26–34]. TGF-β1 can 
inhibit cell proliferation by upregulating the expression of 
several CDK inhibitors, including p21 [27, 35–37], and 
it may thereby directly inhibit the proliferation of tissue 
stem and progenitor cells. Furthermore, TGF-β1 was 
recently described to be required for late-stage neuronal 
development, maturation or survival [38]. Increased 
TGF-β1 signaling could therefore also be a mechanism 
to enhance mature neuronal differentiation or survival in 
addition to its detrimental effects on de-novo neurogenesis. 
However, it may also modulate tissue inflammation, as 
TGF-β1 can be either anti- or pro-inflammatory depending 
on the levels of this morphogen and the gene expression 
landscape of the responding tissue [29, 32]. For example, 
young and healthy levels of TGF-β1 are known to down-
regulate the immune response, and accordingly the 
complete absence of TGF-β1 or its downstream signaling 
causes multifocal inflammation in young mammals 
(reviewed in [32]). In contrast, when present at high or 
pathological levels, TGF-β1 has been shown to promote 
massive inflammation in a variety of systems [29, 32]. 
While inflammatory responses, which in general can 
include induction of MHC class I and/or class II genes 
and the production of multiple inflammatory cytokines 
including TGF-β1, are needed for productive regeneration 
of tissues including skeletal muscle and brain, prolonged 
and excessive inflammation is known to interfere with 
tissue maintenance and repair [7, 29, 32].
We demonstrate an elevation of TGF-β1 in the 
aged circulation, old muscle, and old brain and cross-
tissue conservation in elevated TGF-β/pSmad2,3 signal 
transduction in aged skeletal muscle and neural stem cell 
microenvironments. An ability of circulating TGF-β1 to 
cross the blood brain barrier may increase with age, when 
BBB becomes more permeable [39], but regardless of its 
endocrine levels, local production of TGF-β1 by microglia 
and by endothelial cells increases in the hippocampus 
with aging. Importantly, the age-associated increase in 
TGF-β1 levels leads to a decline in NSC proliferation and 
downstream neurogenesis with age. Moreover, TGF-β 
may exert its pro-aging effects in brain and muscle in part 
by increasing inflammatory responses, as indicated by the 
upregulation of β2 microglobulin (B2M), a component 
of MHC class I molecules. Finally, youthful calibration 
of TGF-β1/pSmad2,3 pathway by a systemically 
administered inhibitor of TGF-β receptor kinase activity 
reduced tissue inflammation in brain and muscle, as 
indicated by normalized levels of B2M, and robustly 
rejuvenated hippocampal neurogenesis and skeletal 
myogenesis in the same old animal.
RESULTS
TGF-β1/pSmad signaling increases in aged 
neural and muscle stem cell niches
Consistent with previously published results 
[13–15], we found that Sox2+BrdU+ proliferating 
Type 1 and 2a hippocampal neural stem and progenitor 
cells significantly decline with age (Figure 1A). 
To determine whether this decrease in proliferating 
neural stem and progenitor cells correlates with levels of 
TGF-β1, we isolated hippocampi from young (2–4 mo) 
and old (22–24 mo) male C57BL6/J mice. Tgfb1 mRNA 
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expression was examined by qRT-PCR, and TGF-β1 
protein levels were analyzed both by ELISA in tissue 
lysates and via immunofluorescence in whole tissue 
sections. As shown in Figure 1B-1E, TGF-β1 became 
elevated with age in the murine hippocampus. Confirming 
a broad age-related increase of TGF-β1, this cytokine 
also became elevated in old blood serum, as assayed by 
both ELISA and Western blotting (Supplemental Data 
Figure 1A and [6]), and old skeletal muscle (Supplemental 
Data Figure 1B, 1C and [28].
TGF-β1 expression has been reported to rise with 
age in the subventricular zone of the forebrain [34, 40, 41], 
contributing to a decline in SVZ neurogenesis. In contrast, 
GDF11, which like TGF-β1 signals through ALK5/
TGFBR2 receptor complex and pSmad2/3, has been 
suggested to enhance SVZ neurogenesis [9]. To investigate 
and reconcile the age-specific expression of multiple TGF-β 
family members in skeletal muscle and hippocampus, we 
performed mRNA and protein analysis. These results 
confirmed an age-specific increase in TGF- β1 in muscle 
and revealed an increase in the hippocampal stem cell 
niche (Supplemental Figure 1B–1C and Figure 1B–1E). 
Interestingly, however, Tgfb2 mRNA did not change with 
age in myofibers, while Tgfb3 and Gdf11 – other TGF-β 
family ligands that signal through SMAD2/3 – were not 
expressed at detectable levels (Supplemental Figure 1D, 
1H, 1I). In addition, qRT-PCR confirmed an increase in 
Tgfb2 and Tgfb3 mRNA levels in aged hippocampi, while 
Gdf11 was expressed in hippocampi but did not change 
with age (Supplemental Figure 1E–1G).
To assess the cellular source of elevated TGF-β 
production, additional immunostaining of astrocytes, 
microglia, and endothelial cells was performed using an 
antibody that reacts with TGF-β1-3. We found that in the 
hippocampus, microglia and endothelial cells, but not 
astrocytes, expressed TGF-β in both old and young dentate 
gyri (Figure 2A-2D), suggesting they are sources of the 
age-associated increases in TGF-β.
To confirm and build upon these results, we analyzed 
downstream pSmad signaling in young versus aged neural 
stem cells in vivo. As shown in Figure 3A (and quantified 
in 3B), the levels of pSmad3 were up-regulated in aged 
compared to young Sox2+ neural stem and progenitor cells 
in the SGZ. Furthermore, TGF-β1 is a known inhibitor of 
cell proliferation [26, 27, 35, 37], and accordingly qRT-
PCR revealed that in vivo hippocampal expression of p21, 
a known down-stream target of TGF-β1/pSmad pathway 
that inhibits cell cycle progression [37, 42], was elevated 
with age (Figure 3C). To probe whether the age-associated 
increase in TGF-β expression may be functionally 
important for neurogenesis, TGF-β1 ligand was added 
to hippocampal-derived Sox2+ neural progenitor cell 
(NPCs) cultures and observed to both upregulate pSmad3 
(Figure 3D) and decrease cell proliferation, as assayed by 
reduced BrdU uptake (Figure 3E-3F). These data are the 
first to profile the age-specific expression of TGF-β family 
ligands in the neurogenic and myogenic tissue niches. 
Furthermore, these data are the first to demonstrate that the 
levels of TGF-β1 transcript and protein and p21 transcript 
increase with age in the hippocampus and particularly in 
microglia, and that SMAD3 phosphorylation increases in 
resident Sox2+ neural stem and progenitor cells of the old 
hippocampus.
Simultaneous systemic enhancement of 
hippocampal neurogenesis and myogenesis 
in old mice
The conserved increase in TGF-β1/pSmad3 
signaling within muscle and brain stem cell niches 
with age suggested that stem cell responses could 
be enhanced in both tissues by attenuating the 
intensity of this pathway, which would both validate 
our conclusions and offer translational potential for 
rejuvenating multiple tissues in the same organism 
with a single therapeutic intervention. Accordingly, 
a small molecule drug pharmacological inhibitor of 
the TGF-β receptor I kinase (Alk5), was added to 
cultured NPCs, where it was found to down-modulate 
pSmad2 and pSmad3 levels (Supplemental Figure 2A, 
quantified in B). In vivo, this drug was administered 
systemically via intraperitoneal (IP) injection into aged 
mice (24–26 months old) once daily for 11 days. In 
mice perfused on day 12, a robust decrease in pSmad2/3 
levels was observed in the hippocampus (Supplemental 
Figure 2C-2F). To assess the ability of the Alk5 inhibitor 
to enhance regeneration of multiple tissues in the same 
animal, muscle was injured by cardiotoxin one week 
after the start of Alk5 inhibitor administration (day 0 
of schematic Figure 4A), and tissue regeneration was 
analyzed at 5 days post-injury (Figure 4A). In parallel, 
we quantified hippocampal neurogenesis – i.e. the 
numbers of BrdU+Sox2+ cells in tissue sections 
across the hippocampus – in the same animal cohorts 
(Figure 4B-4C). Very interestingly, both neurogenesis 
and myogenesis were significantly enhanced in the 
aged mice treated with Alk5 inhibitor, compared to the 
animals receiving control buffer (Figure 4B-4E). In brain 
this was evident from a two-fold increase in the numbers 
of proliferating, Sox2+ neural stem and progenitor cells 
within the hippocampal dentate gyrus (Figure 4B-4C). 
In muscle we observed enhanced de novo myofiber 
formation 5 days post-injury as assayed by quantifying 
the numbers of eMyHC+ fibers with centrally located 
nuclei (Figure 4D, 4E). These results confirmed the pro-
myogenic effects of Alk5 inhibitor [6, 43] and revealed 
that systemic administration of an attenuator of the 
TGF-β/pSmad3 pathway simultaneously rejuvenated 
skeletal myogenesis and hippocampal neurogenesis in 
the same old animal.
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Figure 1: TGF-β increases with age locally in mice hippocampi. A. Young (2 month) and old (24 month) mice (n = 3) were 
administered daily with BrdU for 5 days, followed by perfusion and PFA fixation. Immunofluorescence (IF) was performed for Sox2 (green) 
and BrdU (red), with DAPI (blue) labeling all nuclei. Representative images are shown. Scale bar = 100 μM. B. qRT-PCR quantification of 
Tgfb1 mRNA expression from young and old hippocampi. The relative average expression level was normalized to GAPDH and presented 
as the average expression level relative to that of young hippocampi. Significant differences were identified by Student’s t-tests (two-tailed) 
(*p < 0.003). Error bars indicate standard error of the mean (n = 4 biological replicates per group). C. Immunofluorescence was performed 
on perfused and PFA fixed young and old brain tissue sections (n = 3), for Sox2 (green) and TGF-β1,2,3 (red), with Hoechst (blue) labeling 
all nuclei. Representative low and high magnification images are shown. Scale bars = 50 μM. D. Integrated pixel intensity of TGF-β1,2,3 
immunofluorescence in young and old dentate gyri tissue sections was calculated using ImageJ. Pixel intensities are presented relative to 
young dentate gyri. Significant differences were identified by Student’s t-tests (*p < 0.003). Error bars indicate standard error of the mean 
(n = 3 young, 3 old biological replicates). E. An ELISA was performed on young and old hippocampal protein extract to assess the level of 
local TGF-β1 and represented as the averages of the pg TGF-β1 normalized to pg total hippocampal protein lysate. Significant differences 
were identified by Student’s t-tests (two-tailed) (*p < 0.01). Error bars indicate standard error of the mean (n = 4 young, 5 old biological 
replicates).
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Figure 2: TGF-β is expressed by microglia and endothelial cells. A. Immunofluorescence was performed on perfused old brain 
tissue sections for TGF-β1,2,3 (green), the microglial marker Iba1 (red), and astrocyte marker GFAP (gray), with Hoechst (blue) labeling 
all nuclei. Representative low and high magnification images are shown. Scale bars = 50 μM. Arrows indicate areas of TGF-β and Iba1 
colocalization. B. Immunofluorescence was performed on perfused young brain tissue sections for TGF-β1,2,3 (green), Iba1 (red), and 
GFAP (gray), with Hoechst (blue) labeling all nuclei. Representative low and high magnification images are shown. Scale bars = 50 μM. 
Arrows indicate areas of TGF-β and Iba1 colocalization. C. Immunofluorescence was performed on perfused old brain tissue sections for 
TGF-β1,2,3 (green), endothelial marker CD31 (red), and Sox2 (gray), with Hoechst (blue) labeling all nuclei. Representative low and high 
magnification images are shown. Scale bars = 50 μM. Arrows indicate areas of TGF-β and CD31 colocalization. D. Immunofluorescence 
was performed on perfused young brain tissue sections for TGF-β1,2,3 (green), CD31 (red), and Sox2 (gray), with Hoechst (blue) labeling 
all nuclei. Representative low and high magnification images are shown. Scale bars = 50 μM. Arrow indicates area of TGF-β and CD31 
colocalization.
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Rejuvenation of myogenesis and neurogenesis by 
genetic attenuation of TGF-β signaling
To confirm these findings using independent 
experimental approaches, we inhibited TGF-β signaling 
using a lentivirally-encoded shRNA we developed against 
Smad3. The efficacy of this shRNA was confirmed in 
transduced mouse muscle progenitor cells in vitro via 
western blotting and in mouse neural progenitor cells 
in vitro via qRT-PCR (Supplemental Figure 3A-3B). After 
a single stereotaxic hippocampal injection of a lentiviral 
vector encoding GFP plus the shRNA against Smad3 – 
or a control shRNA against LacZ – into 24 month old 
mice, animals were allowed to recover for 2 weeks, 
followed by five consecutive days of BrdU administration 
(Figure 5A). As shown in Figure 5B–5C, compared to 
control shRNA lentiviral transduction, the numbers of 
Sox2+ proliferating cells (quantified in the GFP+ region 
of tissue sections throughout the entire hippocampus) were 
significantly increased after a single injection of shRNA to 
Smad3. There was also a significantly higher proportion 
of GFP+Sox2+ cells that were also BrdU+ (Figure 5D), 
confirming lentiviral delivery of shRNA against Smad3, 
but not control shRNA, enhanced neural progenitor 
cell proliferation. Neurogenesis was thus significantly 
enhanced by the inhibition of Smad3 signaling in the 
local niche of neural stem cells in 2 year old mice 
(analogous to 80 year old humans), demonstrating 
progress in rejuvenating neurogenesis in very old mice, 
and complementing reports on the enhancement of 
neurogenesis through increase of Wnt-mediated signaling 
in 13 month old mice [44].
Figure 3: Downstream effectors of TGF-β signaling increase with age in mice hippocampi and inhibits neural 
progenitor cell proliferation. A. Immunofluorescence staining for Sox2 (green) and pSmad3 (red) was performed on young and old 
brain tissue sections (n = 4 young, 6 old), with DAPI (blue) labeling all nuclei. Representative images are shown. Scale bar = 50 μM. 
B. MetaXpress image quantification was developed to calculate the average pixel intensity specifically in Sox2+ neural stem and progenitor 
cells in the SGZ of the dentate gyrus. Significant differences were identified by Student’s t-tests (two-tailed) (*p < 0.001). Error bars indicate 
standard error of the mean (n = 4 young, 6 old). C. qRT-PCR quantification of p21 mRNA expression from young and old hippocampi. The 
relative average expression level was normalized by GAPDH and presented relative to young hippocampi. Significant differences were 
identified by Student’s t-tests (two-tailed) (*p < 0.003), and error bars indicate standard error of the mean (n = 3 young, 3 old biological 
replicates per group). D. Immunoblotting analysis of a downstream effector of TGF-β, pSmad3, from NPCs cultured in growth medium in 
the presence or absence of TGF-β1 (50 ng/mL) for 30 minutes. pSmad3 signaling is induced through TGF-β1, as compared with levels of 
total SMAD2/3. E. Functional validation of increasing TGF-β1. NPCs were cultured in growth medium (DMF12 + N2 + 10 ng/mL FGF-2) 
in the presence or absence of TGF-β1 (100 ng/mL) for 24 hrs. A 2 hour BrdU (10 μM) pulse was performed before cell fixation to label 
proliferating cells. Staining was conducted for BrdU (green) and Sox2 (red), with Hoechst (blue) labeling all nuclei. Representative images 
are shown. Scale bar = 100 μM. F. Proliferation of NPCs was quantified by cell scoring in 25 random fields of each condition using an 
automated imager and MetaXpress cell scoring software. Results are displayed as the mean percent of BrdU+ proliferating NPCs +/-SD, 
respectively. Significant differences were identified by Student’s t-tests (two-tailed) (*p < 0.0003), and error bars indicate standard error 
of the mean (n = 4 biological replicates).
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To analyze analogous effects on downstream type 
2b Doublecortin expressing (DCX+) transit amplifying 
cells, another cohort of animals was mitotically 
labeled (with EdU) for 5 consecutive days and studied 
5 days after the final injection to detect the cells that 
had progressed towards neuronal commitment [45]. 
There was a substantial increase in the total number 
of EdU+DCX+GFP+ type 2b cells (Supplemental 
Figure 4A-4C), demonstrating that not only the 
proliferation of neural stem and progenitor cells but the 
generation of neuronally committed cells is enhanced in 
old mice administered with Smad3 shRNA.
To further compare molecular conservation of tissue 
aging between brain and muscle, we also performed a 
single administration of the lentiviral vector encoding 
shRNA against Smad3 into injured hind leg muscle of 
24 month old mice, simultaneously with cardiotoxin to 
induce muscle injury [19, 46]. Significant enhancement 
of old muscle repair, based on the numbers of de-novo 
formed muscle fibers that were quantified throughout the 
entire injury site [19, 47], was observed in the 24 month 
old mice injected with the shRNA to Smad3, compared 
to the control shRNA (Supplemental Figure 4D, 4E), and 
consistent with our prior report [35].
Figure 4: Simultaneous partial rescue of hippocampal neurogenesis and myogenesis in aged mice through systemic 
in vivo inhibition of TGF-β. A. Schematic of Alk5 inhibitor administration. Aged (2 year old) mice received IP injections of TGF-β 
type I receptor kinase Alk5 inhibitor (Alk5i), or vehicle control, once daily for 11 days (Day -6 through Day 4) and were sacrificed on 
Day 5. Tibialis anteriors (TAs) were injured with cardiotoxin on Day 0, and mice began receiving daily IP injections of BrdU through Day 4. 
TAs were collected on Day 5, 5 days post injury (5 dpi). B. Following perfusion and PFA fixation, brain sections of Alk5 inhibitor or vehicle 
treated mice (n = 4 per group) spanning the entire hippocampus were immunostained for BrdU (red) and Sox2 (green), with Hoechst (blue) 
labeling cell nuclei. Representative images are shown. Scale bar = 50 μM. C. Quantification by stereology of BrdU+Sox2+ cells per dentate 
gyrus. As shown, Alk5 type I receptor kinase inhibitor increases the average number of BrdU+Sox2+ cells in the dentate gyrus. Significant 
differences were identified by Student’s t-tests (two-tailed) (*p < 5 × 10−7). Error bars indicate standard error of the mean (n = 4 young, 4 old 
biological replicates) D. TA muscle sections collected 5 days post injury were immunostained for eMyHC (green), with Hoechst (blue) 
labeling cell nuclei. Representative images show newly regenerating myofibers in injured muscle sections. Hematoxylin and eosin staining 
of injury sites are also shown. Scale bars = 100 μM. E. Regenerative index quantifies the number of newly formed eMyHC+ myofibers 
per square millimeter in the injured area. Systemic administration of the Alk5 inhibitor enhances old muscle regeneration after injury, as 
displayed by the mean regenerative index per group. Significant differences were identified by Student’s t-tests (two-tailed) (*p < 0.0002), 
and error bars indicate standard error of the mean (n = 4 biological replicates per group).
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We further corroborated our findings by introducing 
a dominant negative form of the TGF-β1 receptor 
(dnTGFBR2, known to inhibit pSmad2/3 levels [48]). 
Expression of the dnTGFBR2 in neural progenitor cells 
and downstream inhibition of pSmad3 were confirmed 
by western blotting (Supplemental Figure 5A, 5B). 
Retroviral vectors encoding dnTGFBR2 or GFP as a 
control were injected into CTX injured muscle one day 
after injury, when resident muscle stem cells are breaking 
quiescence and entering the cell cycle [1, 19] (Figure 6A). 
Figure 5: Rescue of neurogenesis in aged hippocampi by in vivo genetic inhibition of smad3. A. Schematic of stereotaxic 
lentiviral injection experiment. Aged (18 month old) mice received stereotaxic injections into hippocampi (coordinates from bregma: 
AP: −2.12, ML: +/−1.5, VD: −1.55) of lentiviral vectors encoding shRNA against either Smad3 or lacZ. Mice were allowed to recover 
for 14 days, followed by daily BrdU (50 mg/kg) intraperitonial injections for 5 days, then analysis. B. Brain sections of lacZ or Smad3 
shRNA injected mice (n = 5 lacZ shRNA lentivirus, 4 Smad3 shRNA) spanning the entire hippocampus were immunostained with 
GFP (green), BrdU (red), and Sox2 (gray), with Hoechst (blue) labeling cell nuclei. Representative low and high magnification images 
are shown. Scale bars = 50 μM. Arrows in high magnification image indicate transduced, proliferating NPCs. C. Quantification of the 
mean number of BrdU+Sox2+ cells per dentate gyrus shows an increase in proliferating NPCs in aged animals expressing anti-Smad3 
shRNA. Significant differences were identified by Student’s t-tests (two-tailed) (*p < 0.05). Error bars indicate standard error of the mean 
(n = 5 lacZ shRNA, 4 Smad3 shRNA brains). D. Quantification of the mean percentage of BrdU+GFP+Sox2+ proliferating NPCs as 
compared with BrdU-GFP+Sox2+ NPCs in shRNA injected brains demonstrates an increase in proliferating neural progenitor cells due 
to shRNA-Smad3 transduction as compared with shRNA-lacZ control mice. Significant differences were identified by Student’s t-tests  
(two-tailed) (*p < 4 × 10−7), and error bars indicate standard deviation (n = 3).
Oncotarget11967www.impactjournals.com/oncotarget
Three days after injury, muscle was harvested and assayed 
for proliferating (EdU+) myogenic cells. Compared to 
the aged tissue injected with control vector, in old muscle 
administered with dnTGFBR2 retroviral vector there was 
a marked increase in the percentage of desmin+ muscle 
precursor cells (Figure 6B, 6C) and a significant 
increase in proliferating desmin+EdU+ myogenic cells 
(Figure 6D, 6E). We also examined muscle tissue 5 days 
after injury and observed that repair of old damaged 
muscle in vivo was robustly enhanced by dnTGFBR2, as 
assayed by the replacement of the injury with the newly 
formed myofibers and reduction in scarring (Figure 
6F, 6G). These results extend our previous work [6] to 
in vivo studies and interestingly suggest that retroviral 
delivery of dnTGFBR2 rejuvenated the myogenic capacity 
of old muscle stem cells already responding to tissue 
injury, suggesting that old muscle repair can be enhanced 
after the time of breakage of quiescence (e.g. by enhancing 
the proliferation of the few old muscle stem cells that have 
entered cell cycle). Importantly, these data confirm that 
canonical TGF-β1/pSmad signaling is involved in the age-
imposed inhibition of myogenesis.
To further validate the cross-tissue conservation 
of TGF-β1 signaling with aging, hippocampal neural 
progenitor cells were transduced with dnTGFBR2-
encoding retrovirus and assessed for proliferation. As 
shown in Figure 6H-6I, dnTGFBR2 increased neural 
progenitor proliferation in their (FGF-2-containing) 
growth medium as compared to GFP control, based on 
EdU incorporation. Western blotting analysis showed that 
there was relatively high pSmad3 signaling in NPCs in 
growth medium even in the absence of exogenous TGF-β1, 
which was diminished upon dnTGFBR2 retroviral 
transduction (Supplemental Figure 5A). Furthermore, 
TGF-β1 (10 ng/mL) addition to growth medium overnight 
inhibited proliferation of GFP+ NPCs, but did not affect 
dnTGBR2+ NPCs (Figure 6H, 6I). Collectively, these 
results including both pharmacological and genetic 
intervention suggest that TGF-β1/pSmad2/3 signaling 
increases with age in both myogenic and neurogenic 
niches of tissue stem cells and that attenuation of this 
pathway partially rescues myogenesis and neurogenesis.
High TGF-β levels increase B2M expression in 
aged neural and muscle stem cell niches
The developmental origins and properties of muscle 
and brain (and their respective stem cells) are quite 
different, and we therefore next focused on potential 
underlying molecular mechanisms that may be regulated 
by the pleiotropic TGF-β/pSmad3 pathway and thus shared 
between such adult organ systems. The TGF-β/pSmad3 
pathway exerts complex and sometimes reciprocal effects 
on cellular and tissue responses, including the rate of cell 
cycle progression and the anti- versus pro-inflammatory 
role in regulating immune responses [29]. Thus, we 
next examined the effects of the age-specific elevated 
TGF-β1 on tissue inflammation by assaying the levels of 
MHC class I gene expression, which is known to directly 
associate with and to promote inflammation in multiple 
tissues including in brain and muscle pathologies [40, 
49, 50]. B2M is the invariant chain of the MHC class 
I protein complex, and its expression is regulated similarly 
to the variable/polymorphic MHC class I genes [51–53].
We compared the B2M expression levels as an 
indicator of inflammatory response in young and old 
mice treated with vehicle control, and old mice treated 
with the Alk5 inhibitor (Figure 4). B2M levels were 
extremely low in young brain and muscle, consistent with 
prior work [30], but increased significantly with aging 
(Figure 7A-7E). Importantly, when TGF-β signaling was 
attenuated in vivo by the Alk5 inhibitor, B2M levels were 
significantly diminished both in old brain (Figure 7B, 7C) 
and old muscle (Figure 7D, 7E). These results demonstrate 
that B2M becomes upregulated with aging in multiple 
tissues (suggesting an increase in inflammation) and 
that down-modulation of TGF-β signaling, which 
rejuvenates myogenesis and neurogenesis, normalizes 
B2M in myogenic and neurogenic regions to their young 
levels, suggesting attenuation of inflammation. As further 
support of this conclusion, the levels of B2M were also 
significantly reduced in regenerating regions of the old 
muscle administered with the dnTGFBR2, as compared to 
tissue administered with control GFP virus (Figure 7F, 7G). 
Furthermore, addition of low concentrations of TGF-β1 
(0–5 ng/mL) to immune cells, specifically BV2 cells – 
a microglia cell line – did not affect B2M levels, 
as assayed by pixel intensity and percent area staining of 
B2M (Supplemental Figure 6A-6C). In contrast, high 
TGF-β1 (50 ng/mL) levels induced a significant increase 
in B2M expression. Thus, physiologically young levels 
TGF-β1 does not induce B2M, but increased TGF-β1 does.
DISCUSSION
Collectively, these data are the first to suggest that 
similar molecular mechanisms acutely yet reversibly 
inhibit the capacity of stem cells in old muscle and 
in the hippocampus of the aged brain to contribute to 
differentiated tissue. This study specifically focused 
on age-imposed misregulation of the TGF-β/pSmad3 
signaling pathway, and cross-tissue conservation was 
clearly identified. Confirming these conclusions and 
demonstrating clear therapeutic significance, systemic 
administration of an Alk5 Type I receptor kinase inhibitor 
simultaneously improved repair of skeletal muscle and 
enhanced hippocampal neurogenesis in 2-year old mice, 
suggesting promising strategies for combating multiple 
age-related degenerative disorders, which are known 
to contribute to the loss of a person’s agility, mobility, 
memory, learning, and independence. These results 
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Figure 6: Rescue of myogenesis in aged muscle and enhanced NPC proliferation by in vivo genetic inhibition of 
TGF-β receptor II. A. Schematic. Aged (18 month old) mice TA muscle was injured with cardiotoxin on Day 0, followed by injection 
of dnTGFBR2 retrovirus into injury sites 36 hours later, on Day 1.5. On Day 2 gastrocnemius muscle were injured, followed by injection 
of dnTGFBR2 retrovirus at sites of injury 36 hours later, on Day 3.5. Mice received IP injection of EdU 12 hours before muscle tissue was 
harvested. B. Myogenic precursor cells isolated 3 days post-injury from gastrocnemius muscle were stained for Desmin (red), with Hoechst 
(blue) labeling all cell nuclei. Representative images are shown. Scale bar = 50 μM. C. Quantification of the mean percentage of Desmin+ 
precursor cells. Significant differences were identified by Student’s t-tests (two-tailed) (*p < 0.03). Error bars indicate standard error of 
the mean (n = 3 biological replicates). D. Myogenic precursor cells isolated 3 days post-injury from gastrocnemius muscle were stained 
for Desmin (red) and EdU (green), with Hoechst (blue) labeling all cell nuclei. Representative images are shown. Scale bar = 50 μM. 
E. Quantification of the mean percentage of proliferating myogenic precursor cells isolated from muscle that received dnTGBR2 or GFP. 
Significant differences were identified by Student’s t-tests (two-tailed) (*p < 0.02), and error bars indicate standard error of the mean 
(n = 3 biological replicates per group) F. Hematoxylin and eosin of muscle TAs isolated 5 days post-injury and sectioned in a cryostat 
at 10 μM. Representative images shown. Scale bar = 100 μM. G. Five days post-injury regeneration of old mice tibialis anterior muscle, 
which received dnTGFBR2 or GFP retrovirus, was quantified from muscle sections (10 μM sections throughout sites of injury) and is 
presented as the mean number of newly regenerated myofibers per square millimeter of injury site. Error bars indicate standard error 
of the mean, (n = 3 mice per group). Significant differences were identified by Student’s t-tests (two-tailed) (*p <0.01). H. NPCs were 
transduced with dnTGFBR2 or GFP and cultured for one week, followed by 16 hour incubation in growth medium in the presence/absence 
of 10 ng/mL TGF-β1. Cells were pulsed with EdU (30 μM) for 4 hours before fixation to label proliferating cells. Cells were stained for 
GFP or FLAG (green), EdU (red), and Sox2 (gray), with Hoechst (blue) labeling cell nuclei. Representative images are shown. Scale 
bar = 100 μM. I. Proliferation of NPCs was quantified by cell scoring in 36 random fields of each condition using an automated imager 
and MetaXpress cell scoring software. Results are displayed as the mean percent of EdU+Sox2+ proliferating NPCs +/-SD, respectively. 
Significant differences were identified by Student’s t-tests (two-tailed) (*p < 9 × 10−10, **p < 3 × 10−24, ***p < 4 × 10−16). Error bars indicate 
standard deviation (n = 36 technical replicates). The experiment was replicated 4 times.
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show that excessive TGF-β/pSmad3 signaling induces 
inflammation in muscle and brain, as indicated by 
increased B2M expression. Systemic inhibition of the 
TGF-β type 1 receptor enhanced both neurogenesis and 
myogenesis and normalized B2M levels. An increase in 
inflammation resulting in part from pathologically high 
TGF-β1 levels may contribute to the broad decline in 
maintenance and repair of old tissues by their dedicated 
stem cells, in addition to up-regulation of p21 and other 
cell cycle inhibitors known to occur in skeletal muscle 
[1, 19] described here for the hippocampus.
Independent genetic and pharmacological 
approaches to attenuate TGF-β/pSmad3 signaling drove 
parallel enhancements of neurogenesis and myogenesis, 
Figure 7: B2M levels decrease in neurogenic and myogenic niches following systemic or local attenuation of TGF-β 
signaling. A. qRT-PCR quantification of B2m mRNA expression from young and old hippocampi. The relative average expression level 
was normalized by GAPDH and presented relative to young hippocampi. Significant differences were identified by Student’s t-tests (two-
tailed) (*p < 0.04), and error bars indicate standard error of the mean (n = 4 old, 4 young). B. Brain sections spanning the hippocampus 
from young mice (2 month), as well as Alk5 inhibitor or vehicle treated old (24 month) mice, were immunostained for B2M (red), with 
Hoechst (blue) labeling all cell nuclei. Representative images are shown. Scale bar = 50 μM. C. Average B2M pixel intensity was quantified 
using MetaXpress software, and significant differences were identified by Student’s t-tests (two-tailed) (*p < 3 × 10−6, **p < 0.0001). Error 
bars indicate standard error of the mean (n = 5 young, 3 old + Alk5i, 3 old + vehicle biological replicates (mice), with n = 12 technical 
replicates per mouse) D. Tibialis anterior muscle collected 5 days post-injury were immunostained for B2M (red), with Hoechst (blue) 
labeling all cell nuclei. Representative images are shown. Scale bar = 100 μM. E. Average B2M pixel intensity of 10 μM tibialis anterior 
muscle sections throughout sites of injury were quantified using MetaXpress software. Significant differences were identified by Student’s 
t-tests (two-tailed) (*p < 7 × 10−7, **p < 5 × 10−5), and error bars indicate standard error of the mean (n = 3 biological replicates per group 
(mice), with n = 12 technical replicates per mouse) F. TA muscles collected 5 days post injury were immunostained for B2M (red), with 
Hoechst (blue) labeling all cell nuclei. Representative images are shown. Scale bar = 100 μM. G. Average B2M pixel intensity of TA muscle 
sections throughout sites of injury were quantified using MetaXpress software. Significant differences were identified by Student’s t-tests 
(two-tailed) (*p < 0.002). Error bars indicate standard error of the mean (n = 3 biological replicates per group (mice), with n = 12 technical 
replicates per mouse).
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thus providing important cross- validation of these results 
and conclusions. While local tissue delivery of shRNA 
against Smad3 most likely inhibited TGF-β/pSmad3 
signaling directly in muscle or brain, the systemic 
administration of Alk5 inhibitor could function both 
directly and potentially indirectly through attenuation 
of TGF-β pathway signaling in multiple tissues. Of 
note, both endothelial cells and microglia secrete 
TGF-β (Figure 2). TGF-β signaling is critical for the 
development of microglia and for the maintenance of their 
unique molecular signature in the adult CNS [54], thus 
suggesting that microglia may produce TGF-β for their 
own immunological functions in the brain in addition to 
signaling to other cells. In addition, microglia are known 
both to increase in number in the aged brain and also 
to develop a more inflammatory phenotype with higher 
expression of several cytokines, including TGF-β1 [55]. 
Finally, endothelium may also be a source of elevated 
TGF-β secretion in the hippocampus. Neural stem cells 
are known to be closely associated with blood vessels in 
a vascular niche, where endothelial cells are important 
regulators of neurogenesis that have been reported to 
promote self-renewal and prevent differentiation of NSCs 
through secretion of soluble factors [56]. Furthermore, the 
permissiveness of blood brain barrier increases in the aged 
and pathological brain [57], and the levels of TGF-β1 rise 
with age in circulation ([6], and Supplemental Figure 1), 
suggesting another means by which inhibitory amounts 
of this cytokine could reach the neurogenic SGZ. Finally, 
with potential significance to aging, TGF-β is known to 
be up regulated upon central nervous system damage, and 
such elevation is concurrent with the dramatic induction of 
MHC class I gene expression, as well as with such known 
phenotypes of the aged brain as activation of microglia 
and neuronal apoptosis [30].
Various studies have demonstrated that not just one 
signaling pathway, but a network of highly interactive 
pathways including Notch, Wnt, BMP, Shh, TNF-α, IGF, 
and IL-6 are affected by the aging process [1, 2, 46]. For 
example, Wnt signaling has been demonstrated to decrease 
in aged hippocampi and contribute to the decline of adult 
hippocampal neurogenesis [1, 44, 58, 59]. Furthermore, 
IL-6 becomes elevated in the old and especially at the sites 
of tissue damage [60], is secreted by activated microglia, 
and is known to promote inflammation in part via support 
of Th17 cells and up-regulation of MHC class I and class II 
gene expression [32, 61, 62]. Therefore, it is possible that the 
age-specific increase in TGF-β1 signaling may contribute 
to the excess of IL-6 or other inflammatory cytokines such 
as IL-17, and consequentially experimental attenuation 
of TGF-β1 may result in lower levels of inflammatory 
cytokines and normalized levels of MHC I proteins. The 
detailed understanding of the age-specific cytokine interplay 
in the neurogenic and myogenic niches would be interesting 
to uncover in future comprehensive studies.
In summary, this work improves our understanding 
of the aging of tissue stem cells, reveals a molecular 
conservation of the aging process between muscle and 
hippocampal region of brain, and suggests novel clinical 
strategies for the simultaneous rejuvenation of myogenesis 
and neurogenesis in old mammals.
EXPERIMENTAL PROCEDURES
Animals
Young (2–3 month old) and old (18–24 month old) 
C57BL6/J male mice were purchased from the Jackson 
Laboratory and the NIH. The animal experimental 
procedures were performed in accordance with the Guide 
for Care and Use of Laboratory Animals of the National 
Institutes of Health, and approved by the Office of 
Laboratory Animal Care, UC Berkeley.
For each experiment on aged (18–24 month old) 
mice, an n of at least 7 per group would be used initially. If 
aged mice died due to surgery or age-related health issues, 
a minimum of n = 3 remaining mice were analyzed and 
assessed for statistical significance (described in statistical 
analysis below). Mice of the same genetic strain and age 
were assigned to groups at random.
Cell culture
Primary rat neural progenitor cells isolated from 
the hippocampi of female Fisher 344 rats (Charles 
River) were cultured in growth medium (DMEM/F12 
(Life Technologies) containing N2 supplement (Life 
Technologies) and 10 ng/mL FGF-2 (PeproTech)) on 
laminin (Roche) and polyornithine (Sigma) coated 
tissue culture plates, with subculturing on reaching 80% 
confluency using Accutase (Phoenix Flow Systems), as 
previously described [63].
Primary mouse neural progenitor cells were isolated 
froom C57BL6/J male mice (Charles River) as previously 
described [64]. Cells were cultured in growth medium 
(Neurobasal A (Gibco) containing B27 supplement 
(Gibco), Glutamax-1 supplement (Gibco), 20 ng/mL 
FGF-2 (Peprotech), and 20 ng/mL EGF (PeproTech)) 
on Poly-d-Lysine (Sigma) and Laminin (Roche) coated 
tissue culture plates, with subculturing on reaching 80% 
confluency using Accutase (Phoenix Flow Systems).
Primary mouse muscle progenitor cells 
(myoblasts) were isolated as previously described 
[65] and cultured and expanded in growth medium 
containing: Ham’s F-10 (Gibco), 20% Bovine Growth 
Serum (Hyclone), 5 ng/mL FGF-2 (PeproTech) and 1% 
penicillin-streptomycin on Matrigel (BD Biosciences) 
coated plates (1:300 Matrigel: PBS), with subculturing 
on reaching 80% confluency using 0.5% Trypsin (Sigma 
Aldrich) diluted in PBS.
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Progenitor cells were tested for miscroplasma 
contamination at the UC Berkeley Stem Cell Core Facility 
and using Hoechst DNA stain.
Primary Muscle stem cells were isolated from 
male C57BL6/J mice as described below and cultured in 
DMEM (Life Technologies) with 5% serum from the same 
age mouse on Matrigel (BD Biosciences) coated plates 
(1:100 Matrigel:PBS) overnight before cell fixation with 
70% cold ethanol.
BV2 microglia (gift of Wyss-Coray lab, Stanford), 
were cultured in DMEM (Gibco) + 10% Fetal Bovine 
Serum (Hyclone), with subculturing on reaching 80% 
confluency using 0.5% Trypsin (Sigma Aldrich) diluted 
in PBS.
In vitro validation of TGF-β1 signaling and 
proliferation assay
Primary rat NPCs were cultured in growth medium 
(DMF12 + N2 + 10 ng/mL FGF-2) as described above. 
Cells were cultured at a density of 200,000 cells per 
well of a 6-well culture slide in the presence/absence of 
TGF-β1 (50 ng/mL) (HumanZyme, Inc.) for 30 minutes, 
followed by a PBS wash and cell scraping into RIPA 
buffer for western blot analysis as described below. rNPCs 
were also cultured at a density of 80,000 cells per well 
of an 8-well chamber slide in growth medium plus the 
presence/absence of TGF-β1 (100 ng/mL) for 24 hours. 
NPCs were pulsed for 2 hours with 10 μM BrdU (Sigma 
Aldrich) before cell fixation with 70% cold ethanol for 
immunocytochemistry analysis as described below.
BV2 microglia were cultured in growth medium 
as described above. For experimental treatment, cells 
were then cultured at a density of 80,000 cells per well 
of an 8-well chamber slide in DMEM plus the presence 
of lipopolysaccharide (LPS) (100 ng/mL) (Invivogen) 
and IFN-γ (20 ng/mL) (Peprotech, Inc.) for 24 hours in 
order to stimulate BV2s to an inflammatory activated 
phenotype. TGF-β1 (PeproTech, Inc.) was concurrently 
added to cells for 24 hours at 0–50 ng/mL to assess the 
inflammatory response. After 24 hours, cells were fixed 
with 4% paraformaldehyde for immunocytochemistry 
analysis as described below.
Dissection and preparation of murine 
hippocampi for RNA or protein analysis
Young or old mice were anesthetized and 
perfused with 20 mL saline, followed by dissection of 
hippocampi. For RNA extraction, tissue was placed in 
1 mL Trizol (Invitrogen) and homogenized, followed by 
chloroform extraction as previously described [63]. For 
protein extraction, hippocampi tissue was homogenized 
in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% 
NP40, 0.25% sodium deoxycholate and 1 mM EDTA, 
pH 7.4) containing 1X protease inhibitor (Roche), 
1 mM Phenylmethylsulfonyl fluoride (PMSF), 1 mM 
sodium fluoride and 1 mM sodium orthovanadate. The 
tissue debris was spun at 10K rpm for 5 min at 4C, and 
supernatant containing protein extract snap frozen with 
dry ice.
RNA extraction, RT-PCR and real-time PCR
Total RNA was extracted from primary neural 
progenitor cells or young and old murine hippocampi 
using Trizol reagent (Invitrogen) according to 
manufacturer’s instructions. 1 ug of total RNA was used 
for cDNA synthesis with Olig Dt primers (Invitrogen). 
For real-time PCR amplification and quantification of 
genes of interest, an initial amplification using specific 
primers to each gene of interest (realtimeprimers.com) 
was done with a denaturation step at 95°C for 5 min, 
followed by 45 cycles of denaturation at 95°C for 1 min, 
primer annealing at 58°C for 30 s, and primer extension 
at 72°C for 15 s. Real-time PCR was performed using 
SYBR and an ABI PRISM 7500 Sequence Detection 
System (Applied Biosystems). Reactions were run 
in triplicate in three independent experiments. The 
geometric mean of housekeeping gene GAPDH was 
used as an internal control to normalize the variability 
in expression levels and were analyzed using the 2−ΔΔCT 
method described [66].
ELISA
The concentration of active TGF-β1 in blood serum 
or tissue protein lysate was determined using enzyme-
linked immunoabsorbent assay (ELISA)-based cytokine 
antibody array (R&D), according to manual instructions.
Immunocytochemistry
Mice were anesthetized and perfused with 
saline and 4% PFA. Brains were collected and placed 
in 4% PFA overnight for a post fixation, followed by 
dehydration in 30% sucrose/PBS at 4°C for 2 days. 
Brains were then sectioned at 40 μM using a vibratome 
and stored in a glycerol-based cryoprotectant at −20°C 
until further analysis by immunostaining. For non-
BrdU/EdU staining, sections were washed 3 times for 
15 minutes in TBS, followed by one hour blocking in 
a permeabilization/staining buffer, TBS++ (3% Donkey 
Serum and 0.25% Tween X-100 in TBS), then incubated 
with primary antibodies of interest (see Antibodies) for 
72 hours. For secondary staining, sections were washed 
3 times, 15 minutes each in TBS, followed by 2 hour 
incubation in donkey raised, fluorophore-conjugated, 
species-specific secondary antibodies (Jackson 
Immunoresearch) at 1:250 dilution in TBS++. Following 
secondary staining, sections underwent 3, 15 minute 
washes in TBS, with 4 μM Hoechst in the second wash. 
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Finally, the sections were mounted on positively charged 
frosted slides, dried overnight and imaged with a prairie 
confocal microscope.
BrdU in vivo labeling and immunostaining
Mice were intraperitoneally injected with BrdU 
(50 mg/kg of body weight, Sigma Aldrich) dissolved in 
saline to label mitotic cells. Sections were incubated in 
SSC/formamide at 65°C water for 2 hours, washed 
in TBS, followed by 2N HCl for 15 minutes. They 
were then placed in 2X Saline-Sodium Citrate (SSC) 
for 30 minutes, .1 mM Borate Buffer for 15 minutes, 
followed by 6, 15 minute washes in TBS, then blocked 
in a permeabilization/staining buffer, TBS++ for 2 hours. 
Sections were then incubated with αRat-BrdU (Abcam 
Inc. ab6326) and other antibodies (see Antibodies section) 
in TBS++ at 4°C for 72 hours. Secondary staining was 
done as described above.
EdU in vivo labeling and immunostaining
Mice were intraperitoneally injected with EdU 
(50 mg/kg of body weight, Invitrogen) dissolved in 
phosphate-buffered saline to label mitotic cells. Brain 
sections were post-fixed with 4% PFA for 30 minutes 
after primary and secondary staining, and treated for EdU 
visualization using the Click-iT EdU kit (Invitrogen), as 
per the manual’s instructions.
Muscle progenitor cells were fixed with cold, 70% 
ethanol and stained for αRabbit-Desmin and secondary 
staining as described below under muscle methods. 
Following secondary staining, cells were treated for EdU 
visualization using the Click-iT EdU kit (Invitrogen), as 
per the manual’s instructions.
Western blot analysis
Primary neural or muscle progenitor cells, or whole 
muscle tissue were lysed in RIPA buffer (50 mM Tris, 
150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate 
and 1 mM EDTA, pH 7.4) containing 1X protease 
inhibitor (Roche), 1 mM Phenylmethylsulfonyl fluoride 
(PMSF), 1 mM sodium fluoride and 1 mM sodium 
orthovanadate. The protein concentration was determined 
by Bradford assay (Bio-Rad). Lysates were resuspended 
in 1X Laemmli buffer (Bio-Rad), boiled for 5 minutes 
and separated on precast 7.5% or 4–15% TGX gels 
(Biorad). Primary antibodies were diluted in 5% non-
fat milk in TBS + 0.1% Tween-20, and nitrocellulose 
membranes were incubated with antibody mixtures 
overnight at 4°C. HRP-conjugated secondary antibodies 
(Santa Cruz Biotech) were diluted 1:500 in 5% non-fat 
milk in TBS + 0.1% Tween-20 and incubated for 1 hour 
at room temperature. Blots were developed using Western 
Lightning ECL reagent (Perkin Elmer), and analyzed 
with Bio-Rad Gel Doc/Chemi Doc Imaging System and 
Quantity One software. Results of multiple assays were 
quantified using Applied Biosystems or Image J software. 
Pixel Intensity of bands of interest were normalized 
with pixel intensity of glyceraldehydes-3-phosphate 
dehydrogenase or β-actin.
Antibodies
αRabbit-pSmad2 (Millipore AB3849), αRabbit-
βactin (Cell Signaling #4967), αMouse-TGFβ1 (R&D 
MAB240), αMouse-TGFβ1,2,3 (R&D MAB1835), 
EdU Click-it kit (Invitrogen C10337 and C10338), 
αGuineyPig-DCX (Millipore AB2253), αGoat-Sox2 
(Santa Cruz SC-17320), αRabbit-Desmin (Abcam 
ab32362), αMouse-embryonic myosin heavey 
chain (eMyHC) (Hybridoma Bank, clone F1.652), 
αChicken-GFP (Abcam ab13970), αRabbit-FLAG 
(Santa Cruz sc-807), αMouse-FLAG (Abcam 
ab18230), αRabbit-pSmad3 (Epitomics #1880-1), 
αRat-BrdU (Abcam ab6326), TGF-β1 ELISA kit (R&D 
DY1679), αMouse-Smad2/3 (Santa Cruz sc-133098), 
αRabbit-B2M (Abcam ab75853), αGoat-GapDH 
(Abcam ab9483), αRat-CD31 (BD Biosciences 550274), 
αGoat-Iba1 (Abcam ab5076), αRabbit-GFAP (Abcam 
ab7260).
In vitro validation of Alk5 inhibitor in rNPCs
Following overnight rNPC culturing in growth 
medium at a density of 300,000 cells per well of a 6 well 
tissue culture plate, rNPCs were starved in a basal medium 
(lacking FGF-2) for 1 hour, then untreated, or treated with 
1 ng/mL TGF-β1 for 1 hour in the presence/absence of 
5 uM of Alk5 inhibitor, followed by a PBS wash and cell 
scraping to collect cells into RIPA buffer for western blot 
analysis.
In vivo validation of Alk5 inhibitor
Aged (24 month old) C57BL6/J male mice were 
injected intraperitonially (IP) with TGF-β1 Type I 
Receptor Kinase Alk5 inhibitor 2-(3-(6-Methylpyridin-
2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine (Enzo Life 
Sciences) diluted in sunflower seed oil to a concentration 
of 57.4 μM. Mice (n = 4) received 100 uL IP injections 
of the Alk5 inhibitor or vehicle control once daily for 
11 days, and were perfused on the 12th day. Tibialis 
Anterior muscle was injured with cardiotoxin after one 
week of IP injections, on day 7 (as described below in 
muscle methods). Additionally, on day 7 we began daily 
IP BrdU injections (50 mg/kg body weight). Four hours 
after receiving the fifth BrdU IP injection, the mice were 
perfused (on Day 12), and brains and TAs were collected 
for analysis.
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Lentiviral and retroviral vector construction, 
packaging, and purification
A DNA cassette encoding human U6 promoter-
driven expression of shRNA against mouse Smad3 (Gene 
ID: 17127) was constructed by PCR with flanking Pac I 
sites and, following restriction digestion and phenol/
chloroform purification, ligated into the Pac I site of the 
pFUGW lentiviral vector. Five candidate sequences were 
tested for knockdown efficiency, and the most effective 
sequence (shSMAD 3.4 in Supplemental Table 1) was 
selected for experimental studies. Sequences for all 
shRNAs tested are provided in Supplemental Table 1. 
The control shRNA vector against LacZ was constructed 
previously [63]. PCR was performed with Phusion DNA 
Polymerase (New England Biolabs) under the following 
conditions: 98°C for 2 min, 30 cycles of 12 s at 95°C, 
30 s at 65°C, and 25 s at 72°C, with a final extension 
step of 2 min at 72°C. Lentiviral and retroviral vectors 
were packaged and purified using standard methods as 
described [67].
A dominant negative TGFBR2 retroviral plasmid 
was obtained (Addgene, Cambridge, MA, http://www.
addgene.org/12640/) and packaged and purified as 
previously described [68].
In vitro validation of smad3 shRNA vector
Mouse myoblasts were cultured for 24 hours at 
a density of 100,000 cells per well of a 6 well tissue 
culture plate in 50% growth medium and 50% lentiviral 
supernatant (in DMEM + 10% FBS), packaged as 
previously described [68], followed by culturing in 
growth medium for a total of 72 hours. Cells were then 
washed once with PBS, scraped and collected into RIPA 
for western blot analysis.
mNPCs were plated at 200,000 cells per well 
of a 6 well tissue culture plate in growth medium, and 
transduced with lentivirus encoding shRNA to Smad3 
or lacZ at a multiplicity of infection (MOI) of 5 and 
cultured for two weeks. RNA was extracted with Trizol 
(Invitrogen) followed by qPCR to assess levels of Smad3 
(see Supplemental Table 1 for sequences).
In vivo loss of function with shRNA
Aged (18 month) C57BL6/J male mice received 
lateral intrahippocampal injections of 1 μl of lentiviral 
solutions (LV-shRNA-Smad3-GFP or LV-shRNA-lacZ-
GFP, 1–3 × 10^8 IU/mL) in PBS on day -14, on the right 
hemisphere hippocampus, at 0.25 uL per minute. The 
injection coordinates with respect to bregma were -2.12 
anteriorposterior, -1.55 dorsoventral (from the dura), and 
1.5 mediolateral (refer to Figure 5A). Mice were allowed 
to recover 14 days, followed by BrdU IP injections 
(50 mg/kg bodyweight) 1X daily for 5 days. One day after 
receiving the fifth BrdU IP injection, mice were saline and 
4% PFA perfused. Immunostaining and Quantification 
described elsewhere.
Aged (18 month) C57BL6/J male mice received 
lateral intrahippocampal injections of 1 μl of lentiviral 
solutions (LV-shRNA-Smad3-GFP or LV-shRNA-lacZ-
GFP, 1–3 × 10^8 IU/mL) in PBS on day -14, on the right 
hemisphere hippocampus, at 0.25 uL per minute. The 
injection coordinates with respect to bregma were -2.12 
anteriorposterior, -1.55 dorsoventral (from the dura), and 
1.5 mediolateral (refer to Supplemental Figure 4). Mice 
were allowed to recover 14 days, followed by EdU IP 
injections (50 mg/kg bodyweight) 1X daily for 5 days. 
Five days after receiving the fifth EdU IP injection, mice 
were saline and 4% PFA perfused. Immunostaining and 
Quantification described elsewhere.
shRNA muscle injection
Aged (24 month) C57BL6/J male mice were injured 
with CTX in the tibialis anterior (TA) muscle in two sites 
as described below, and on the following day 5 μl of 
concentrated lentiviruses carrying Smad3 shRNA or LacZ 
shRNA were injected to the injury sites using a 30 gauge 
needle. Mice TAs were harvested 5 days post injury, as 
described below.
In vitro validation of dnTGFBR2 vector
Neural progenitor cells (NPCs) were transduced 
with retroviruses carrying dominant negative TGFBR2 
(Addgene, Cambridge, MA, http://www.addgene.
org/12640/) which has a cytoplasmic truncation and a 
FLAG tag, or GFP control and cultured for 72 hours. GFP 
and dnTGFBR2-transduced cell lysates were prepared 
as described in western blotting methods, and probed on 
western blots for the FLAG-tagged dnTGFBR2 using 
anti-FLAG antibody (Santa Cruz), GFP (Abcam), pSmad3 
(Epitomics), Smad2/3 (Santa Cruz), and βactin (Cell 
Signaling). Transduced NPCs were also plated at 300,000 
cells per well of a 6-well tissue culture plate and cultured 
in basal medium (DMF12 + N2) after cell splitting for 
4 hours, followed by 45 minute treatment with 0, 1, or 
12.5 ng/mL TGF-β1. Cell pellets were lysed in 100 uL 
RIPA buffer, and probed on western blots for pSmad3, 
Smad2/3, and βactin.
For proliferation assay, NPCs were transduced 
with 3 μL concentrated retroviruses per 3 × 105 cells, 
delivering dnTGFBR2 or GFP and cultured for one week. 
Transduced NPCs were then split at 80,000 cells per 
well into 8-well chamber slides and cultured overnight 
in growth medium (DMF12 + N2 + 10 ng/mL FGF-2) 
in the presence/absence of 10 ng/mL TGF-β1. 16 hours 
post addition of TGF-β1, cells were pulsed for 4 hours 
with EdU (30 μM). Cells were fixed with 4% PFA for 
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20 minutes, and immunostained for FLAG (Abcam), GFP 
(Abcam), EdU (Invitrogen), and Sox2 (Santa Cruz), as 
described in immunocytochemistry methods.
In vivo muscle injection of dnTGFBR2 retrovirus
Aged (18 month) C57BL6/J male mice were injured 
with CTX in the tibialis anterior muscle in two sites and in 
the gastrocnemius muscle in four sites as described below, 
and 5 μl of concentrated retroviruses carrying dnTGFBR2 
or GFP control were injected to the injury sites using a 
30 gauge needle at different time points (see Figure 6 
for details). Mice received EdU IP injection (50 mg/kg) 
12 hours before muscle harvest at 5 days post injury.
Muscle injury
Isoflurane was used to anesthetize the animal during 
the muscle injury procedure. For bulk myofiber satellite 
cell activation, gastrocnemius muscles were injected with 
cardiotoxin 1 (Sigma) dissolved at 100 micrograms per 
milliliter in PBS, at 4 sites of 5 microliters each for each 
muscle. Muscles were harvested 3 days later. For focal 
injury to assay regeneration by immunoanalysis and 
histology, 5 microliters of 0.5 milligram per milliliter 
CTX was injected to two sites at the middle of the tibialis 
anterior muscle, and muscle harvested 5 days later.
Muscle fibers and muscle progenitor 
cell isolation
Injured gastrocnemius muscle was dissected from 
old mice and incubated at 37°C in digestion medium 
(150 U/mL Collagenase type II in DMEM medium, 
buffered with 30 mM HEPES) for 2 hours. Digested 
muscle was gently triturated and myofibers were collected. 
Myofibers were further digested with 1 U/mL Dispase 
and 40 U/mL Collagenase type II to liberate muscle stem 
cells [65]. Muscle stem cells were cultured in DMEM 
(Life Sciences) with 5% serum from the same age mouse.
Muscle tissue immunofluorescence 
and histological analysis
Muscle tissue was dissected, flash frozen in OCT 
compound (Tissue Tek; Sakura) and cryo-sectioned at 
10 micrometers. Cryo-sectioning was performed through 
the entire volume of muscle (50–70 sections total, done 
at 200 μm intervals), thereby serially sampling the 
entire tissue. Muscle sections were stained with aqueous 
hematoxylin and eosin (H&E), as per the manufacturer’s 
instructions (Sigma-Aldrich). Regeneration and myogenic 
potential was quantified by examining injury sites from 
representative sections along the muscle spanning the 
injury, then by measuring the injured area using Adobe 
Photoshop Elements. Myofiber regeneration was quantified 
by counting total newly regenerated fibers and dividing 
by the regeneration area. Immunostaining was performed 
as described [69]. Briefly, after permeabilization in 
PBS + 1% FBS + 0.25% Triton-X-100, tissues and cells 
were incubated with primary antibodies in staining buffer 
(PBS + 1% FBS) for 1 h at room temperature, followed by 
1 h incubation fluorochrome-labeled secondary antibodies 
(ALEXA at 1:1000). BrdU-specific immunostaining 
required an extra step of 2 M HCl treatment before 
permeablization.
Whole muscle tissue analysis
Whole muscle from young and old resting TA 
and TA adjacent to cardiotoxin injured gastrocnemius 
muscle was isolated and lysed as described earlier [7]. In 
brief, muscles were lysed using Miltenyi Biotec Tissue 
Dissociator in tissue lysate buffer and lysates were run on 
7.5% Criterion gel (BioRad) and western blotted against 
TGF-β1 (R&D, mouse monoclonal antibody) and GAPDH 
(Abcam, goat polyclonal) antibody. The images were 
quantified using Image J software and P values calculated 
using student’s t-test.
Quantification and statistical analysis
For quantification of immunofluorescent images 
for BrdU incorporation, 25 20x images per replicate 
were taken on the Molecular Devices ImageXpress 
Micro automated epifluorescence imager, followed by 
automated cell quantification using the multiwavelength 
cell scoring module within the MetaXpress analysis 
software. Data was analyzed using Student’s t-tests 
(two-tailed) and P values equal or lower than 0.05 were 
considered statistically significant. Sample sizes of n = 3 
or greater were determined for each experiment based on 
power analysis and IACUC considerations, and based 
on previously published experimental group numbers 
[19, 44, 63] and assessed for significance based on 
p values and heteroscedastic variance between groups 
that were statistically compared. For pixel intensity and 
percent area quantifications of immunofluorescent images, 
MetaXpress Analysis Software or ImageJ were used to 
determine integrated pixel intensity and percent positive 
area of thresholded images.
For quantification of the number of BrdU+Sox2+ 
cells in Alk5 inhibitor treated mice, unbiased stereology 
(Zeiss Axio Imager, software by MicroBrightfield) using 
the optical fractionator method was performed on 8 
vibratome coronal brain slices spanning the hippocampus 
(40 microns thick, 200 microns apart), and the number 
of selected cells was normalized by the volume of 
hippocampal tissue analyzed. For quantification of the 
number of BrdU+Sox2+ or EdU+DCX+ cells in shRNA 
viral vector injected brains, confocal stacks of 8 vibratome 
coronal GFP+ brain slices spanning the hippocampus 
Oncotarget11975www.impactjournals.com/oncotarget
(40 microns thick, 200 microns apart) were acquired on a 
Prairie confocal microscope and cells were counted. Cell 
numbers were normalized to the volume of the DG granule 
cell layer measured by ImageJ and as previously described 
[59]. Briefly, volume was calculated based on a threshold 
of the granule layer of each image as determined with 
Hoechst staining, then calculating the volumetric fraction 
based on the thickness of the brain slice (40 μM) and the 
interval at which hippocampi sections were analyzed 
(every 6th section).
Inclusion/exclusion criteria
Only aged mice that died during the study due to 
health reasons were excluded from analysis. In terms of 
automated counting of cells using MetaXpress analysis 
software, only sites that were blurry with indistinguishable 
colors (such as areas on the slide with bubbles or sites 
imaged with incorrect focus by the Molecular Devices 
ImageXpress Micro automated epifluorescence imager), 
or areas with large cell clumps were excluded from 
the cell quantification analysis. These criteria were 
pre-established.
When performing in vivo experiments, such as 
Alk5 inhibitor injections or shRNA steretaxic brain 
injections, there was no blinding. For quantification and 
analysis, researchers were blinded to the group allocation, 
specifically when doing regenerative index calculations, 
stereology and cell counts.
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